The treatment of schizophrenia: Can we raise the standard of care?

Australian and New Zealand Journal of Psychiatry

Volumn 50, Issue 12, 2016, Pages 1128-1138

  Catts, Stanley Victor ^a,b,c   O'Toole, Brian Ignatius ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

algorithm; medication; outcomes; Schizophrenia; treatment

Indexed keywords

NEUROLEPTIC AGENT;

BRAIN SIZE; CLINICAL EFFECTIVENESS; DISEASE COURSE; GRAY MATTER; HUMAN; MAINTENANCE THERAPY; MENTAL HEALTH CARE; MORTALITY RATE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RELAPSE; RELIABILITY; REVIEW; SCHIZOPHRENIA; HEALTH CARE QUALITY; STANDARDS;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; STANDARD OF CARE;

EID: 85002335969     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867416672725     Document Type: Review

References (90)

1. Andreasen NC, Liu D, Ziebell S, et al. (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: A prospective longitudinal MRI study. American Journal of Psychiatry 170: 609-615.
2. Ascher-Svanum H, Faries DE, Zhu B, et al. (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67: 453-460.
3. Bleuler M, (1978 [1972]) The Schizophrenic Disorders: Long-term Patient and Family Studies (trans. Clemens SM,). New Haven, CT: Yale University Press.
4. Bora E, Fornito A, Yucel M, et al. (2010) Voxelwise meta-analysis of grey matter abnormalities in bipolar disorder. Biological Psychiatry 67: 1097-1105.
5. Breitborde NJK, Bell EK, Dawley D, et al. (2015) The Early Psychosis Intervention Centre (EPICENTER): Development and six-month outcomes of an American first-episode psychosis clinical service. BMC Psychiatry 15: 266.
6. Brown E, Gray R, (2015) Tackling medication non-adherence in severe mental illness: Where are we going wrong? Journal of Psychiatric and Mental Health Nursing 22: 192-198.
7. Byerly MJ, Thompson A, Carmody T, et al. (2007) Validity of electronic monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatric Services 58: 844-847.
8. Catts SV, O'Toole BI, Carr VJ, et al. (2010) Appraising evidence for intervention effectiveness in early psychosis: Conceptual framework and review of evaluation approaches. Australian & New Zealand Journal of Psychiatry 44: 195-219.
9. Chiliza B, Ojagbemi A, Esan O, et al. (2016) Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting. Early Intervention in Psychiatry 10: 54-62.
10. Ciompi L, (1980) The natural history of schizophrenia in the long term. British Journal of Psychiatry 136: 420-423.
11. Curson DA, Barnes TR, Bamber RW, et al. (1985) Long-term depot maintenance of chronic schizophrenic outpatients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial: III relapse postponement or relapse prevention? The implications for long-term outcome. British Journal of Psychiatry 146: 474-480.
12. Department of Health and Ageing (2013) National Mental Health Report 2013: Tracking Progress of Mental Health Reform in Australia 1993-2011. Canberra, ACT, Australia: Commonwealth of Australia, p. 32, Figure 5.
13. Doessel DP, Williams RFG, Whiteford H, (2010) The trend in mental health-related mortality rates in Australia 1916-2004: Implications for policy. Australia and New Zealand Health Policy 7: 3.
14. Dolder CR, Lacro JP, Dunn LB, et al. (2002) Antipsychotic medication adherence: Is there a difference between typical and atypical agents? American Journal of Psychiatry 159: 103-108.
15. Dolder CR, Lacro JP, Leckband S, et al. (2003) Interventions to improve antipsychotic medication adherence: Review of recent literature. Journal of Clinical Psychopharmacology 23: 389-399.
16. Early Psychosis Guidelines Writing Group (2010) Australian Clinical Guidelines for Early Psychosis, 2nd Edition. Melbourne, VIC, Australia: ORYGEN Youth Health.
17. Emsley R, Nuamah I, Hough D, et al. (2012) Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophrenia Research 138: 29-34.
18. Emsley R, Oosthuizen P, Koen L, et al. (2013) Comparison of treatment response in second-episode versus first-episode schizophrenia. Journal of Clinical Psychopharmacology 33: 80-83.
19. Farooq S, Farooq N, (2014) Tackling medication nonadherence in psychiatric disorders: Current opinion. Neuropsychiatric Disease and Treatment 10: 1069-1077.
20. Farooq S, Naeem F, Singh S, (2016) Editorial: Telling the patients about diagnosis and outcome of schizophrenia: What, when and how? Early Intervention in Psychiatry 10: 101-102.
21. Fernandes BS, Steiner J, Berk M, et al. (2015) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: Meta-analysis and implications. Molecular Psychiatry 20: 1108-1119.
22. First MB, Williams JBW, Karg RS, et al. (2015a) Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA: American Psychiatric Association.
23. First MB, Williams JBW, Karg RS, et al. (2015b) User's Guide for the Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA: American Psychiatric Association.
24. French P, Smith J, Shiers, et al, et al. (eds) (2010) Promoting Recovery in Early Psychosis: A Practice Manual, 1st Edition. Oxford: John Wiley & Sons.
25. Freudenreich O, Schulz SC, Goff DC, (2009) Initial medical work-up of first-episode psychosis: A conceptual review. Early Intervention in Psychiatry 3: 10-18.
26. Fusar-Poli P, Smieskova R, Kempton MJ, et al. (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience and Biobehavioral Reviews 37: 1680-1691.
27. Gaebel W, Riesbeck M, Wolfgang W, et al. (2016) Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. Schizophrenia Research 170: 168-176.
28. Galletly C, Castel D, Dark F, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry 50: 410-472.
29. Gilmer TP, Dolder CR, Lacro JP, et al. (2004) Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161: 692-699.
30. Girgis RR, Philips MR, Li X, et al. (2011) Clozapine v. chlorpromazine in treatment-naïve first episode schizophrenia: 9-year outcomes of a randomised clinical trial. British Journal of Psychiatry 199: 281-288.
31. Gopal S, Vijapurkar U, Lim P, et al. (2011) A 52 week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psychopharmacology 25: 685-697.
32. Griswold KS, Del Regno PA, Berger RC, (2015) Recognition and differential diagnosis of psychosis in primary care. American Family Physician 91: 856-863.
33. Haijma SV, Van Haren N, Cahn W, et al. (2013) Brain volumes in schizophrenia: A meta-analysis in over 18,000 subjects. Schizophrenia Bulletin 39: 1129-1138.
34. Jaaskelainen E, Juola P, Hirvonen N, et al. (2013) A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin 39: 1296-1306.
35. Joshi D, Catts VS, Olaya JC, et al. (2015) Relationship between somatostatin and death receptor expression in the orbital frontal cortex in schizophrenia: A post-mortem brain mRNA study. npj Schizophrenia 1: Article 14004.
36. Kane JM, Kishimoto T, Correll CU, (2013) Assessing the comparative effectiveness of long-acting injectables vs oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Psychiatry 66: S37-S41.
37. Kishimoto T, Nitta M, Borenstein M, et al. (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. Journal of Clinical Psychiatry 74: 957-965.
38. Kishimoto T, Robenzadeh A, Leucht C, et al. (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin 40: 192-213.
39. Kusumi I, Boku S, Takahashi Y, (2015) Psychopharmacology of atypical antipsychotic drugs: From receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences 69: 243-258.
40. Lacro JP, Dunn LB, Dolder CR, et al. (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry 63: 892-909.
41. Leucht C, Heres S, Kane JM, et al. (2011) Oral versus depot antipsychotic drugs for schizophrenia: A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research 127: 83-92.
42. Lieberman JA, Alvir JM, Koreen A, et al. (1996) Psychobiological correlates of treatment response in schizophrenia. Neuropsychopharmacology 14: 13S-21S.
43. Lieberman JA, Alvir JM, Woerner M, et al. (1992) Prospective study of psychobiology in first episode schizophrenia at Hillsdale Hospital. Schizophrenia Bulletin 18: 351-371.
44. Lieberman JA, Jody D, Geisler S, et al. (1993) Time course and biological correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 50: 369-376.
45. Lieberman JA, Tollefson GD, Charles C, et al. (2005) Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 62: 361-370.
46. Llorca PM, Abbar M, Courtet P, et al. (2013) Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13: 340.
47. McEvoy IP, Hogarty GE, Steingard S, (1991) Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 48: 739-745.
48. McGorry P, Edwards J, (1997) The Early Psychosis Training Pack. Melbourne, VIC, Australia: Gardiner-Caldwell Communications Ltd and the Early Psychosis prevention and Intervention Centre, p. 21.
49. McMillen JC, Lenze SL, Hawley KM, et al. (2009) Revisiting practice-based research networks as a platform for mental health services research. Administration and Policy in Mental Health 36: 308-321.
50. Malla A, Norman R, Schmitz N, et al. (2006) Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychological Medicine 36: 649-658.
51. Merlo MCG, Hofer H, Gekle W, et al. (2002) Risperidone 2 mg/day vs 4 mg/day in first episode acutely psychotic patients: Treatment efficacy and effects on fine motor functioning. Journal of Clinical Psychiatry 63: 885-891.
52. Morgan VA, Waterreus A, Jablensky A, et al. (2012) People living with psychotic illness in 2010: The second Australian national survey of psychosis. Australian & New Zealand Journal of Psychiatry 46: 735-752.
53. Mueser KT, Deavers F, Penn DL, Cassisi JE, (2013) Psychological treatments for schizophrenia. Annual Review of Clinical Psychology 9: 465-497.
54. 2-receptor occupancy method in the rat. European Journal of Pharmacology 540: 7-90.
55. Oosthuizen P, Emsley R, Turner HJ, et al. (2004) A randomised controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. International Journal of Neuropsychopharmacology 7: 125-131.
56. Pantelis C, Velakoulis D, McGorry PD, et al. (2003) Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. The Lancet 361: 281-288.
57. Reininghaus U, Dutta R, Dazzan P, et al. (2015) Mortality in schizophrenia and other psychoses: A 10-year follow-up of the AESOP First-Episode cohort. Schizophrenia Bulletin 41: 664-673.
58. Ren W, Lui S, Deng W, et al. (2013) Anatomical and functional brain abnormalities in drug-naïve first-episode schizophrenia. American Journal of Psychiatry 170: 1308-1316.
59. Robinson DG, Woerner MG, Alvir JMJ, et al. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56: 241-247.
60. Robinson DG, Woerner MG, McMeniman M, et al. (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161: 473-479.
61. Roe D, Yanos PT, (2006) Psychoeducation for people with psychotic symptoms: Moving beyond information and towards inspiration. The Behavior Therapist 29: 53-56. Available at: www.abct.org/docs/PastIssue/29n3.pdf
62. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines (RANZCP CPG) Team for the Treatment of Schizophrenia and Related Disorders (2005) Royal Australian & New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related Disorders. Australian & New Zealand Journal of Psychiatry 39: 1-30.
63. Rusch N, Corrigan PW, (2002) Motivational interviewing to improve insight and treatment adherence in schizophrenia. Psychiatric Rehabilitation Journal 26: 23-32.
64. Saha S, Chant D, McGrath J, (2007) A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time. Archives of General Psychiatry 64: 1123-1131.
65. Scully PJ, Coakley G, Kinsella A, et al. (1997) Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychological Medicine 27: 1303-1310.
66. Sheline YI, Gado MH, Kraemer HC, (2003) Untreated depression and hippocampal volume loss. American Journal of Psychiatry 160: 1516-1518.
67. Shimazono Y, (1973) Comment and discussion. In: Mitsuda H, Fukada T, (eds) Biological Mechanisms of Schizophrenia and Schizophrenia-like Psychosis. Tokyo, Japan: Igaku Shoin Ltd., pp. 126-128.
68. Takeuchi H, Suzuki T, Uchida H, et al. (2012) Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. Schizophrenia Research 134: 219-225.
69. Tiihonen J, Haukka J, Taylor M, et al. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168: 603-609.
70. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin 41: 656-663.
71. Treadway MT, Waskom ML, Dillon DG, et al. (2015) Illness progression, recent stress, and morphology of hippocampal subfields and medial prefrontal cortex in major depression. Biological Psychiatry 77: 285-294.
72. Valenstein M, Kavanagh J, Lee T, et al. (2011) Using pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophrenia Bulletin 37: 727-736.
73. Van Haren NE, Hulshoff Pol HE, Schnack HG, et al. (2007) Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study. Neuropsychopharmacology 32: 2057-2066.
74. Van Haren NE, Hulshoff Pol HE, Schnack HG, et al. (2008) Progressive brain volume loss in schizophrenia over the course of the illness: Evidence of maturational abnormalities in early adulthood. Biological Psychiatry 6: 106-113.
75. Velligan DI, Diamond PM, Mintz J, et al. (2008) The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophrenia Bulletin 34: 483-493.
76. Velligan DI, Lam F, Ereshefsky L, et al. (2003) Perspectives on medication adherence and atypical antipsychotic medications. Psychiatric Services 54: 665-667.
77. Velligan DI, Wang M, Diamond P, et al. (2007) Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services 58: 1187-1192.
78. Vita A, De Peri L, Deste G, et al. (2015) The effect of antipsychotic treatment on cortical grey matter changes in schizophrenia: Does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biological Psychiatry 78: 403-412.
79. Waddington JL, Youssel HA, Kinsella A, (1995) Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological Medicine 25: 849-857.
80. Wagner EH, (2000) The role of patient care teams in chronic disease management. British Journal of Medicine 320: 569-572.
81. Watt DC, Katz K, Shepherd M, (1983) The natural history of schizophrenia: A 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment. Psychological Medicine 13: 663-670.
82. Weiden PJ, Roma RS, Velligan DI, et al. (2015) The challenge of offering long-acting antipsychotic therapies: A preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. Journal of Clinical Psychiatry 76: 684-690.
83. Wey MC, Loh SY, Doss JG, et al. (2016) The oral health of people with chronic schizophrenia: A neglected public health burden. Australian & New Zealand Journal of Psychiatry 50: 685-694.
84. Wiersma D, Nienhuis FJ, Slooff CJ, et al. (1998) Natural course of schizophrenic disorders: A 15-Year Follow-up of a Dutch incidence cohort. Schizophrenia Bulletin 24: 75-85.
85. Wunderink L, Nieboer RM, Wiersma D, et al. (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70: 913-920.
86. Wyatt RJ, (1991) Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17: 325-351.
87. Zhang W, Deng W, Yao L, et al. (2015) Brain structural abnormalities in a group of never-medicated patients with long-term schizophrenia. American Journal of Psychiatry 172: 995-1003.
88. Zipursky RB, Menezes NM, Streiner DL, (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophrenia Research 152: 408-414.
89. Zipursky RB, Reilly TJ, Murray RM, (2013) The myth of schizophrenia as a progressive brain disease. Schizophrenia Bulletin 39: 1363-1372.
90. Zygmunt A, Olfson M, Boyer CA, et al. (2002) Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159: 1653-1664.